Monitoring of Perfusion in Sepsis and Malaria (PERFuSE)

June 18, 2021 updated by: University of Oxford

Perfusion and Lung Congestion Evaluation Related to Fluids and Vasopressors in Sepsis and Malaria. (PERFuSE): an Observational Study

Sepsis and severe malaria together contribute to an estimated 13 million deaths annually, a great burden of which is in low-income countries. Optimal fluid management is critical yet remains one of the most challenging clinical care elements as volume overload precipitates pulmonary edema and volume restriction may exacerbate acute kidney injury. These complications of sepsis and severe malaria significantly increase mortality, particularly in resource-limited settings lacking mechanical ventilation and renal replacement therapy. Point-of-care ultrasound and passive leg raise testing are two easily implementable, safe and non-invasive clinical bedside fluid assessment tools that could be applied towards developing a fluid management algorithm in low resource settings. Similarly, simple tissue perfusion measures can facilitate understanding of precise indications or contraindication to fluid and vasopressor therapy.

However, the performance of these tools has yet to be confirmed in these settings. Accurate assessment of pulmonary tolerance and fluid responsive patients could aid to tailor vasopressor and fluid therapy to the patient condition and disease phase, thus preventing or detecting iatrogenic pulmonary edema and other pulmonary complications. As there is currently limited evidence supporting fluid management recommendations for severe malaria and sepsis in low-resource settings, the potential application of these management tools could optimize supportive therapy and improve outcomes in these populations.

The main activity proposed is a prospective, observational study of patients with sepsis and severe malaria to describe the relationship between fluid therapy and vasopressor therapy against measures of tissue perfusion and pulmonary congestion in adult patients with severe malaria or severe sepsis. In addition, the study will assess the performance of simple bedside clinical tools assessing fluid responsiveness, pulmonary congestion and peripheral tissue perfusion.

The data from this observational study will facilitate the preparation of a follow-up study to test a clinical algorithm to guide individualized fluid and vasopressor administration.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This will be a single center, prospective, longitudinal, observational study of patients with sepsis or severe malaria. It is planned that this initial observational study will inform a follow-up intervention study, based on the observational study findings (Lung Ultrasound and Passive Leg Raising- guided Vasopressors and Fluid Management in Patients with Sepsis and Severe Malaria). The follow-up study will propose testing of a clinical algorithm to individualize titration of vasopressors, diuretics and fluids based on the simple tools evaluated during the observational study.

The expected duration of study patient participation is 30 days. Patients will be assessed every 6 hours until fever clearance, parasite clearance (in malaria patients) and GCS normalization (score of 15) on two consecutive assessments. Thereafter, patients will be assessed daily until discharge or death with one follow-up visit at 14 days and a follow-up call at day 30. The prospective, observational recruitment phase of the study is expected to last 15 months.

Funder: Wellcome Trust of Great Britain, Grant reference number: 220211/A/20/Z

Study Type

Observational

Enrollment (Actual)

103

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Chittagong, Bangladesh
        • Chittagong medical College hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Male or female subjects, aged ≥12 years hospitalized with malaria or sepsis.

Description

Inclusion Criteria:

I. Sepsis criteria:

The sepsis criteria include the severe sepsis and septic shock categories according to 2012 Surviving Sepsis Campaign guidelines. Due to a possible delay in obtaining all the enrolment sequential organ failure assessment (SOFA) score variables necessary to fulfil the criteria for the latest 2016 sepsis definition, the 2012 Surviving Sepsis Campaign criteria and the quick SOFA tool will be used for inclusion. However, after study completion, when all admission SOFA scores will be available, all patients will be re-scored according to the Sepsis 3 definition.

Inclusion criteria for sepsis:

  1. Documented or suspected infection
  2. Systolic blood pressure ≤ 100 mmHg, or receiving vasopressor (epinephrine, norepinephrine, dopamine)

    PLUS one or more of the following:

    A. Respiratory rate ≥22 breaths per minute or under oxygen therapy or mechanical ventilation B. Altered mental status (Glasgow Coma Scale ≤ 14)

  3. Fully informed written consent obtained, including written informed consent from a relative or parent/guardian in case of reduced consciousness and/or age < 16 years.
  4. Age ≥12 years
  5. Negative peripheral blood slide for any stages of malaria parasites and a negative rapid diagnostic test (RDT) for falciparum and vivax malaria.
  6. Within 24 hours of hospital or ICU admission

Note: Positive blood or urine cultures not required as eligibility criteria due to limited microbiology laboratory availability.

II. Severe malaria criteria Using modified World Health Organization criteria for severe falciparum malaria, as defined previously.

  • Any P. falciparum or P. vivax parasitaemia in adults, detected by asexual stages on a peripheral blood- slide or a positive RDT in combination with one or more:

    i. GCS <11 ii. Hematocrit < 20% with parasite count >100,000/mm3 iii. Jaundice with parasite count >100,000/mm3 iv. Serum creatinine >3 mg/dL (or anuria) v. Hypoglycemia with venous glucose <40 mg/dL vi. Systolic blood pressure <80 mmHg with cool extremities vii. Peripheral asexual stage parasitemia >10 % viii. Peripheral venous lactate >4 mmol/L ix. Peripheral venous bicarbonate <15 mmol/L x. Respiratory distress/pulmonary edema: radiologically confirmed, or oxygen saturation <92% on room air with a respiratory rate >30/min, often with chest indrawing and crepitations on auscultation xi. Spontaneous bleeding xii. Generalized convulsions (≥2 in 24 hours)

  • Fully informed written consent obtained, including written informed consent from relative or parent/guardian in case of reduced consciousness and/or age < 16 years.
  • Age ≥12 years
  • Within 24 hours of antimalarial treatment

III. Uncomplicated malaria criteria (control group)

  • P. falciparum slide positive (asexual stages) on peripheral blood slide or positive RDT in combination with none of the above severity criteria.
  • Within 24 hours of start of antimalarial treatment
  • Fully informed written consent obtained, including written informed consent from relative or parent/guardian in case of reduced consciousness and/or age < 16 years.
  • Age ≥12 years

Exclusion Criteria

The participant may not enter the study if ANY of the following apply:

  • Patients admitted with known malignancy or liver disease
  • Recent surgery (as part of current admission)
  • Trauma (resulting in current admission)
  • Antimalarial treatment ≥24 hours prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Sepsis
Use of lung ultrasound to detect pulmonary complications
CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
Measurement of the inferior vena cava diameter
Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
Measurement of capillary flow in the rectal microcirculation
For urinalysis, biochemistry, urine microscopy, pH, and culture.
for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
all patients will have an ECG performed on enrolment as a non-invasive investigation
GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
Severe malaria
Use of lung ultrasound to detect pulmonary complications
CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
Measurement of the inferior vena cava diameter
Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
Measurement of capillary flow in the rectal microcirculation
For urinalysis, biochemistry, urine microscopy, pH, and culture.
for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
all patients will have an ECG performed on enrolment as a non-invasive investigation
GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
Uncomplicated malaria
Use of lung ultrasound to detect pulmonary complications
CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
Measurement of the inferior vena cava diameter
Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
Measurement of capillary flow in the rectal microcirculation
For urinalysis, biochemistry, urine microscopy, pH, and culture.
for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
all patients will have an ECG performed on enrolment as a non-invasive investigation
GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fluid balance volume at 24 hours
Time Frame: On the first 24 hours from enrollment
Fluid balance volume in milliliters calculated daily as inputs minus outputs.
On the first 24 hours from enrollment
Plasma lactate levels
Time Frame: 72 hours
Plasma venous lactate levels expressed in mmol/L
72 hours
Vasopressor therapy
Time Frame: 72 hours
Expressed as dichotomous variable, use of any vasopressor during the first 72 hours.
72 hours
Global ultrasound aeration score
Time Frame: 72 hours
The score ( range 0-36) is calculated over 12 lung zones where each zone is scored 0 to 3.
72 hours
Fluid balance volume at 48 hours
Time Frame: On the first 48 hours from enrollment
Fluid balance volume in milliliters calculated daily as inputs minus outputs.
On the first 48 hours from enrollment
Fluid balance volume at 72 hours
Time Frame: On the first 72 hours from enrollment
Fluid balance volume in milliliters calculated daily as inputs minus outputs.
On the first 72 hours from enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma creatinine levels
Time Frame: 48 hours
Measured in millimoles per liter.
48 hours
Positive chest X-ray for pulmonary edema (dichotomous variable)
Time Frame: 72 hours
Other measures evaluating pulmonary congestion
72 hours
The ratio between pulse oxymetry hemoglobin saturation and the fraction of inspired oxygen (SpO2/FiO2 ratio).
Time Frame: 72 hours
Other measures evaluating pulmonary congestion
72 hours
Proportion of fluid responsive patients
Time Frame: 72 hours
Fluid responsiveness is defined as a positive pulse pressure passive leg raise test (change in pulse pressure >10% after leg raise manouver) or cardiac output-guided passive leg raise test (change in cardiac output >10% after leg raise manouver). The passive leg raise test is performed both a standard maneuver (bed tilting) and a modified maneuver (manual leg raise).
72 hours
Prolonged capillary refill time (dichotomous variable, defined as ≥3 seconds)
Time Frame: 72 hours
Other measures evaluating tissue perfusion
72 hours
Skin mottling score (0-5)
Time Frame: 72 hours
Other measures evaluating tissue perfusion
72 hours
Cardiac index (in liters per minute per square meter of body surface area)
Time Frame: 72 hours
Other measures evaluating tissue perfusion
72 hours
Core-periphery temperature gradient(°C)
Time Frame: 72 hours
Other measures evaluating tissue perfusion
72 hours
Proportion of patients at enrolment and during admission with a low cardiac index and hypoperfusion state.
Time Frame: 72 hours
72 hours
Proportion of patients with microvasculature obstruction or abnormalities
Time Frame: 24 hours
Microvasculature obstruction and abnormalities are detected with orthogonal polarization spectral imaging (OPS); red cell deformability is studied by laser assisted rotational cell analyser (LORCA).
24 hours
Proportion of patients that develop pulmonary edema and acute respiratory distress syndrome (ARDS).
Time Frame: 72 hours
Pulmonary edema is defined as the presence of 2 or more positive lung zones per hemithorax on the lung ultrasound. Acute respiratory distress syndrome is defined according to the Berlin Definition criteria.
72 hours
Case fatality in first 30 days.
Time Frame: 30 days
30 days
Acute kidney injury (AKI)
Time Frame: At admission, up to day 14, and renal recovery by 30 days
Proportion of AKI as per Kidney Diseases Improving Global Outcomes definition: serum creatinine increase by ≥ 3 mg/dl within 48 hours, or serum creatinine increase by ≥ 1.5 times baseline, or urine volume <0.5 mg/kg/h for 6 hours. Outcome of AKI defined as renal recovery (time in days until creatinine returns to baseline).
At admission, up to day 14, and renal recovery by 30 days
Proportion of patients that develop lower extremity deep venous thrombosis.
Time Frame: 72 hours
Deep venous thrombosis is defined as a positive compressive ultrasonography on femoral or popliteal veins of lower limbs.
72 hours
Microbiological etiology of sepsis.
Time Frame: 72 hours
Results of blood culture and organism identified in case of positive result
72 hours
Number of patients with ARDS according to the Kigali Modification of the Berlin Definition of ARDS
Time Frame: 72 hours
72 hours
Diagnostic performance measures (sensitivity, specificity, positive predictive value, negative predictive value) of the digital microscope with expert microscopy as the gold standard
Time Frame: 7 days
7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 4, 2018

Primary Completion (Actual)

August 29, 2019

Study Completion (Actual)

September 26, 2019

Study Registration Dates

First Submitted

May 29, 2018

First Submitted That Met QC Criteria

August 17, 2018

First Posted (Actual)

August 22, 2018

Study Record Updates

Last Update Posted (Actual)

June 21, 2021

Last Update Submitted That Met QC Criteria

June 18, 2021

Last Verified

September 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • MAL18001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malaria

Clinical Trials on Lung Ultrasound examination

Search Similar Trials